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A BS T R AC T
BACKGROUND

The prioritization of U.S. health care personnel for early receipt of messenger RNA
(mRNA) vaccines against severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the
evaluation of the effectiveness of these new vaccines in a real-world setting.
METHODS

We conducted a test-negative case–control study involving health care personnel
across 25 U.S. states. Cases were defined on the basis of a positive polymerasechain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–
like symptom. Controls were defined on the basis of a negative PCR test for SARSCoV-2, regardless of symptoms, and were matched to cases according to the week
of the test date and site. Using conditional logistic regression with adjustment for
age, race and ethnic group, underlying conditions, and exposures to persons with
Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days
after receipt of the first dose through 6 days after receipt of the second dose) and
complete vaccination (assessed ≥7 days after receipt of the second dose).

The authors’ full names, academic de‑
grees, and affiliations are listed in the
Appendix. Address reprint requests to
Dr. Pilishvili at tdp4@cdc.gov.
*A list of the investigators of the Vaccine Ef‑
fectiveness among Healthcare Personnel
Study Team is provided in the Supplemen‑
tary Appendix, available at NEJM.org.
Drs. Verani and Schrag contributed equally
to this article.
This article was published on September 22,
2021, at NEJM.org.
N Engl J Med 2021;385:e90.
DOI: 10.1056/NEJMoa2106599
Copyright © 2021 Massachusetts Medical Society.

RESULTS

The study included 1482 case participants and 3449 control participants. Vaccine
effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to
82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2)
with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age
(<50 years or ≥50 years), race and ethnic group, presence of underlying conditions,
and level of patient contact. Estimates of vaccine effectiveness were lower during
weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose,
but confidence intervals overlapped widely.
CONCLUSIONS

The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world
conditions in preventing symptomatic Covid-19 in health care personnel, including
those at risk for severe Covid-19 and those in racial and ethnic groups that have
been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)
n engl j med 385;25
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ealth care personnel are at
increased risk for exposure to severe
acute respiratory syndrome coronavirus
2 (SARS-CoV-2), the virus that causes coronavirus
disease 2019 (Covid-19), through interactions in
the workplace related to care and proximity to
patients, in addition to household and community
interactions.1 In December 2020, two messenger
RNA (mRNA) vaccines, the BNT162b2 vaccine
from Pfizer–BioNTech and the mRNA-1273 vaccine from Moderna, were approved by the Food
and Drug Administration under Emergency Use
Authorization for use among persons 16 years of
age or older (for the BNT162b2 vaccine) or
among those 18 years or older (for the mRNA1273 vaccine).2-4 The U.S. Advisory Committee on
Immunization Practices recommended the prioritization of health care personnel during earlyphase distribution of these vaccines5 to ensure
that critical services were maintained and that
the spread of infection in health care settings
was reduced.5 Vaccination of health care personnel in the United States was initiated in December 2020, and by early March 2021, more than
half the frontline health care personnel in the
United States had been vaccinated with Covid-19
vaccines.6
Phase 3 clinical trials showed the safety and
efficacy of the mRNA vaccines,7,8 and early data
from observational studies9-11 have supported the
clinical trial results. Real-world data on vaccine
effectiveness are useful for building on evidence
from clinical trials and continuing to inform
Covid-19 vaccine policy. The randomized, controlled trials were not powered to evaluate efficacy among persons with chronic illness or among
those in racial and ethnic minority groups that
have been disproportionately affected by Covid-19.
To evaluate the effectiveness of mRNA vaccines in preventing Covid-19 among health care
personnel in the United States, we conducted a
multisite, test-negative case–control study involving health care personnel who had been
tested for SARS-CoV-2. The interim results of
this study showing the effectiveness of the receipt of either mRNA vaccine have been published
previously.12 Here, we report the full study results with the extended enrollment through May
2021. We evaluated effectiveness according to
vaccine product for partial and complete vaccination and in subgroups defined according to age,
race and ethnic group, presence of underlying
n engl j med 385;25
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conditions, estimated level of patient contact,
and the time from receipt of two vaccine doses.

Me thods
Study Population

Our study population included health care personnel who had been tested for SARS-CoV-2.
Participants were enrolled from December 28,
2020 (2 weeks after the introduction of a Covid-19
vaccine), through May 19, 2021, at 33 sites across
25 U.S. states, representing more than 500,000
health care personnel (Table S1 in the Supplementary Appendix, available with the full text of
this article at NEJM.org). The majority (68%) of
the participating facilities were acute care hospitals (with or without affiliated outpatient and
urgent care clinics), and 32% were long-term
care facilities. Covid-19 vaccines were introduced
at the participating facilities in December 2020,
and the vaccine coverage among health care
personnel at these facilities reached 55 to 98%
for the receipt of at least one dose of vaccine and
51 to 94% for the receipt of two vaccine doses
during the study period.
The study protocol was reviewed by the
Centers for Disease Control and Prevention and
the institutional review board at each participating medical center and was conducted in accordance with federal laws and institutional policies.
The authors vouch for the accuracy and completeness of the data reported and for the fidelity of the study to the protocol.
Study Design

We conducted a test-negative case–control study
involving health care personnel, a group that comprised all paid and unpaid health care personnel
with the potential for direct exposure to patients
or the potential for indirect exposure to infectious materials at the workplace.13 Testing for
SARS-CoV-2 was based on occupational health
practices at each facility and was leveraged to
identify cases and controls for this study. Case
participants were defined as health care personnel who had at least one Covid-19–like symptom
and a positive result for SARS-CoV-2 on polymerase-chain-reaction (PCR) testing, other nucleic acid amplification testing, or antigen-based
testing.14 The index test date (date that the specimen was obtained) for cases was the first SARSCoV-2–positive test for the episode of Covid-19–
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like illness for which case participants were
enrolled. The illness was defined as symptomatic
if the participant had at least one of the following symptoms present within 14 days before or
after the index test date: fever (a body temperature documented at ≥38°C or subjective fever),
chills, cough (dry or productive), shortness of
breath, chest pain or tightness, fatigue or malaise,
sore throat, headache, runny nose, congestion,
muscle aches, nausea or vomiting, diarrhea, abdominal pain, altered sense of smell or taste,
loss of appetite, or red or bruised toes or feet.
Persons who tested negative on PCR or other
laboratory-based nucleic acid amplification testing, regardless of symptoms, were eligible for
inclusion as controls. Control participants were
matched to case participants according to site of
enrollment and week of test date. Within any
given week and study site, any participants who
tested positive for SARS-CoV-2 (cases) and those
who tested negative (controls) and agreed to complete a survey or to be interviewed were matched,
with a target ratio of three controls per case.
Persons with previous infection, defined as a
positive SARS-CoV-2 test (on PCR or antigen
testing) that had occurred more than 60 days
before the index test date, were excluded.
Information on the participants’ demographic
characteristics, symptoms of Covid-19–like illness, underlying conditions and risk factors associated with severe Covid-19,15 and medical care
received was collected by means of interviews or
participant-completed surveys. The interviews
and surveys also included information on potential confounders related to workplace and community behaviors. Medical records were reviewed in order to collect information about the
SARS-CoV-2 test, including the date, test type,
and result, and about the medical care sought
during the Covid-19–like illness. Information on
Covid-19 vaccination dates and products received
was obtained from occupational health clinics,
vaccine cards, state registries, or medical records.
Vaccination Status

Vaccination status of the participants was determined at the time of their SARS-CoV-2 test date.
Participants were considered to be unvaccinated if
they had not received any dose of Covid-19 vaccine as of the test date. We defined the interval
from days 0 through 13 after receipt of the first
dose as the time before effectiveness from a
n engl j med 385;25

single dose is expected. We further stratified
this interval to evaluate for a potential early effect of the first dose by measuring vaccine effectiveness at 0 to 9 days and at 10 to 13 days
after receipt of the first dose, on the basis of the
cutoff when vaccine effectiveness after the first
dose was measured both in this study and in
clinical trials.1,7
The effectiveness of a single vaccine dose was
measured from 14 days after receipt of the first
dose through 6 days after receipt of the second
dose (partially vaccinated). We conducted a sensitivity analysis to evaluate the effectiveness of a
single vaccine dose before receipt of the second
dose to exclude potential early effects after receipt of the second dose. In an additional sensitivity analysis that evaluated the potential influence of vaccine-related reactions leading to the
testing of health care personnel, we excluded
participants who had been tested within 0 to
2 days after receipt of the second dose. The effectiveness of two doses of vaccine was measured at 7 days or more after receipt of the second dose (complete vaccination), which was
consistent with the Pfizer–BioNTech clinical
trial.7 In a sensitivity analysis, we also evaluated
the effectiveness of two doses of vaccine at 14
days or more after receipt of the second dose,
which was consistent with the Moderna trial.8
Statistical Analysis

We used conditional logistic regression to estimate vaccine effectiveness as 1 minus the matched
odds ratio (× 100%) for partial vaccination or
complete vaccination as compared with no vaccination. We evaluated the influence of age, race
and ethnic group, presence of underlying medical conditions or risk factors for severe Covid-19,
and other factors related to community and workplace behaviors, such as the use of personal protective equipment and receipt of influenza vaccine during the current respiratory season, as
potential confounders for vaccine effectiveness
by including each variable with vaccination status in the model and then retaining variables
that resulted in a change of more than 10% in
the model estimate for vaccination status.
In the final model, we adjusted for age, race
and ethnic group, presence of at least one underlying condition or risk factor for severe Covid-19,
and close contact with patients with Covid-19 in
the workplace or with persons with Covid-19
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outside the workplace. We evaluated vaccine effectiveness according to vaccine product and in
subgroups defined according to participants’
age (<50 years or ≥50 years), race and ethnic
group, presence of underlying conditions, health
care job categories, and clinical case definitions
that were consistent with those used in the
clinical trials. We examined the adjusted vaccine
effectiveness according to 2-week intervals of
follow-up after receipt of the second dose (as
compared with unvaccinated participants) to assess for waning of vaccine effect. All the statistical analyses were conducted with the use of SAS
software, version 9.4 (SAS Institute).

R e sult s
Characteristics of Health Care Personnel

During the study period of December 28, 2020,
through May 19, 2021, a total of 109,865 health
care personnel were tested across the participating sites; of these persons, 8365 (7.6%) tested
positive for SARS-CoV-2. A total of 1482 participants with a positive test and at least one Covid-19–
like symptom (cases) and 3449 with a negative
test (controls) were enrolled. Among the enrolled
health care personnel, 69% worked at acute care
hospitals (including emergency departments),
31% in outpatient or specialty clinics, 1% in urgent care clinics, and 1% in long-term care facilities.
The characteristics of the enrolled participants
are shown in Tables 1 and 2. More than three
quarters of the participants (76% of the cases
and 75% of the controls) reported having at least
one underlying condition associated with an increased risk of severe Covid-19, and no differences were noted in the distribution of individual
conditions or risk factors between cases and
controls, with the exception of obesity (more
common among case participants) and asthma
(more common among control participants) (Table S2). We identified 62 cases among pregnant
women; the median gestational age at the time
of the index test date was 23 weeks (range, 3 to
41). The most common underlying conditions
were obesity (in 36% of the case participants and
in 31% of the control participants), overweight
(in 29% and 28%, respectively), asthma (in 14%
and 18%), and hypertension (in 15% and 14%).
Only 2% of case participants were hospitalized
during their illness; 1% of control participants
e90(4)
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were hospitalized during a non–Covid-19–related illness. No deaths were reported among the
participants included in this study.
A total of 45% of the case participants and
74% of the control participants had received at
least one dose of Covid-19 vaccine at any time
before the test date. Among vaccinated participants, 78% of the cases and 79% of the controls
had received the BNT162b2 vaccine; 21% and
20%, respectively, had received the mRNA-1273
vaccine. The remaining participants had received
the ChAdOx1 nCoV-19 vaccine from AstraZeneca
(in 2 cases and 1 control) or the Ad26.COV2.S
vaccine from Johnson & Johnson (in 8 cases and
28 controls) and were excluded from the analyses of vaccine effectiveness. A higher proportion
of control participants than case participants
had received one vaccine dose at least 14 days
before their test date and had received two doses
at least 7 days before their test date.
We identified 167 cases among completely
vaccinated participants and 140 cases among partially vaccinated participants (Table 3). The characteristics of the completely and partially vaccinated case participants and the unvaccinated
case participants are shown in Table S3. Among
completely vaccinated case participants, the median length of time after receipt of the second
dose to the index test date was 41 days (range,
7 to 165); the median interval between the two
doses was 21 days (range, 17 to 42) for the
BNT162b2 vaccine and 28 days (range, 24 to 32)
for the mRNA-1273 vaccine. The proportion of
participants who had severe symptoms or were
hospitalized was higher among unvaccinated case
participants than among partially or completely
vaccinated case participants.
Vaccine Effectiveness

For the period of 0 to 9 days after receipt of the
first dose, the vaccine effectiveness was 12.8%
(95% confidence interval [CI], −9.4 to 30.5).
Vaccine effectiveness at 10 to 13 days after
receipt of the first dose was 36.8% (95% CI, 14.8
to 53.1). The adjusted effectiveness for partial
vaccination with any vaccine was 79.7% (95% CI,
74.1 to 84.1) and was similar with both the
BNT162b2 vaccine (77.6%; 95% CI, 70.9 to 82.7)
and the mRNA-1273 vaccine (88.9%; 95% CI,
78.7 to 94.2) (Table 3). Results of sensitivity analyses for partial vaccination were similar when
effectiveness was measured before receipt of the
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Table 1. Demographic Characteristics of Health Care Personnel Who Tested Positive for SARS-CoV-2 and Had One
or More Symptoms of Covid-19–like Illness (Case Participants) and Those Who Tested Negative (Control Participants)
at 33 U.S. Sites, January to May 2021.*
Case Participants
(N = 1482)

Control Participants
(N = 3449)

Standardized
Difference†

37 (18–69)

37 (18–78)

0.0831

18–49 yr

1134 (77)

2590 (75)

0.0333

50–64 yr

Characteristic
Age
Median (range) — yr
Distribution — no. (%)

318 (21)

743 (22)

0.0021

≥65 yr

17 (1)

80 (2)

0.0899

Missing data

13 (1)

36 (1)

0.0171

250 (17)

574 (17)

0.0061

1222 (82)

2863 (83)

0.0146

12 (<1)

0.0458

Sex — no. (%)
Male
Female
Other

10 (1)

Race and ethnic group — no. (%)‡
White, non-Hispanic

980 (66)

2502 (73)

0.1395

Black, non-Hispanic

188 (13)

259 (8)

0.1724

Hispanic or Latino

160 (11)

284 (8)

0.0874

Asian or Pacific Islander, non-Hispanic

84 (6)

269 (8)

0.0851

American Indian or Alaska Native, non-Hispanic

34 (2)

47 (1)

0.0696

Multiple or other, non-Hispanic

17 (1)

38 (1)

0.0043

Unknown

19 (1)

50 (1)

0.0144

107 (7)

125 (4)

0.1593

1029 (69)

1923 (56)

0.2855

335 (23)

1383 (40)

0.3840

11 (1)

18 (1)

0.0278

1255 (85)

2733 (79)

0.1419

Government

82 (6)

162 (5)

0.0380

None

19 (1)

20 (1)

0.0732

126 (9)

534 (15)

0.2161

Educational level — no. (%)
High school or less
Undergraduate or technical degree
Graduate or professional degree
Unknown
Health insurance — no. (%)
Private

Unknown

*	Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus disease 2019, and SARS-CoV-2 se‑
vere acute respiratory syndrome coronavirus 2.
†	The standardized difference shows the difference in means in units of the pooled standard deviation (Section E in the
Supplementary Appendix).
‡	Race and ethnic group were reported by participants.

second dose (74.0%; 95% CI, 66.1 to 80.1) and
when the analyses excluded the period of 0 to 2
days after receipt of the second dose (76.3%;
95% CI, 69.6 to 81.5). The adjusted effectiveness
for complete vaccination was 90.4% (95% CI,
87.0 to 92.9) and was similar with either of the
two mRNA vaccines; effectiveness that was asn engl j med 385;25

sessed at 14 days or more after receipt of the
second dose also showed similar results (88.9%;
95% CI, 84.7 to 92.0).
Sensitivity analyses that excluded asymptomatic controls resulted in estimates of vaccine effectiveness for partial vaccination of 82.1% (95%
CI, 76.6 to 86.3) and for complete vaccination of
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Table 2. Workplace and Community Behaviors of Health Care Personnel Who Tested Positive for SARS-CoV-2 and Had One or More Symptoms
of Covid-19–like Illness (Case Participants) and Those Who Tested Negative (Control Participants).
Variable
Anticipated level of patient contact, assessed on the basis of job category — no. (%)†
Substantial direct patient contact
Moderate direct patient contact
Minimal direct patient contact
Undefined patient contact
Community behaviors 14 days before symptom-onset date or test date — no. (%)
Had close contact with a person with Covid-19 outside the health care setting‡
Had close contact with any ill person outside a health care facility‡
Attended a gathering that included persons other than household members
Used public or shared transportation
Attended or worked at a school or day care
Had a household member who attended school or day care
Workplace behaviors
Had close contact with a person with Covid-19 who was not a patient — no. (%)
Had close contact with a patient with Covid-19 during work in health care
facility — no. (%)
Used personal protective equipment appropriately — no./total no. (%)§¶
Participated in aerosol-generating procedures for patients with
Covid-19 — no./total no. (%)§‖
Had exposure to patients with Covid-19 who were not intubated or
wearing face coverings — no./total no. (%)§
All or most of the time
Sometimes
Rarely or never
Not sure
Reason for SARS-CoV-2 test — no. (%)**
Occupational exposure in the workplace
Exposure outside the workplace
Routine screening, with no symptoms
Presence of symptoms
Other**
Reported previous positive result of serologic test during study interview — no. (%)

Case Participants
(N = 1482)

Control Participants
(N = 3449)

Standardized
Difference*

918 (62)
168 (11)
340 (23)
56 (4)

2227 (65)
394 (11)
702 (20)
126 (4)

0.0545
0.0028
0.0629
0.0066

665 (45)
518 (35)
390 (26)
225 (15)
72 (5)
367 (25)

638 (18)
731 (21)
753 (22)
650 (19)
201 (6)
998 (29)

0.5911
0.3098
0.1050
0.0976
0.0431
0.0942

250 (17)
479 (32)

624 (18)
1142 (33)

0.0322
0.0168

206/479 (43)
180/479 (38)

519/1142 (45)
434/1142 (38)

0.0326
0.0133

129/479 (27)
60/479 (13)
83/479 (17)
207/479 (43)

308/1142 (27)
170/1142 (15)
250/1142 (22)
414/1142 (36)

0.0080
0.0425
0.0672
0.0585

192 (13)
327 (22)
63 (4)
1182 (80)
14 (1)
17 (1)

493 (14)
449 (13)
541 (16)
2229 (65)
97 (3)
14 (<1)

0.0390
0.2396
0.3888
0.3426
0.1379
0.0845

*	The standardized difference shows the difference in means in units of the pooled standard deviation (Section E in the Supplementary Appendix).
†	Job categories that were associated with anticipated substantial direct patient contact included the following: physician, physician assistant,
nurse practitioner, registered nurse, licensed practical nurse, other nurse, certified nursing assistant, patient care technician or assistant, medi‑
cal assistant, coronavirus disease 2019 (Covid-19) tester, phlebotomist, home health personnel, emergency medical services provider, physical
therapist or assistant, rehabilitation aide, occupational therapist, speech–language pathologist, respiratory therapist, radiology technician, dental
health care provider, and surgical, medical, or emergency technician. Job categories that were associated with anticipated moderate direct patient
contact included the following: environmental services personnel, food services personnel, patient transport personnel, nonphysician behavioral
health provider, chaplain, care coordinator, translator, health educator, genetic counselor, dietitian, and research personnel. Job categories that
were associated with minimal patient contact included the following: administrative or ward clerk, symptom checker, telehealth trainer, facilities
maintenance equipment and sterile technician, medical equipment salesperson, laboratory personnel, and pharmacist. Undefined patient con‑
tact included other health care personnel who could not be classified into any of the above categories and those with missing information.
‡	Close contact was defined as being within approximately 6 ft (approximately 2 m) of a person with Covid-19 for at least 15 minutes or hav‑
ing unprotected direct contact with potentially infectious secretions or excretions.
§	This measure was assessed among participants who reported close contact with patients with Covid-19 during work.
¶	Appropriate use of personal protective equipment during care for patients with Covid-19 was defined as the wearing of an N95 mask or
powered air-purifying respirator, gown, gloves, and face shield or goggles at all times.
‖	Aerosol-generating procedures were defined as follows: airway suctioning, breaking the ventilation circuit (intentionally or unintentionally), bronchosco‑
py, chest physiotherapy, cardiopulmonary resuscitation, high-flow oxygen delivery (whether by nasal cannula or mask), high-frequency oscillatory ventila‑
tion, intubation, mini–bronchoalveolar lavage, manual (bag) ventilation, nebulizer treatments, noninvasive positive-pressure ventilation (e.g., bilevel posi‑
tive airway pressure or continuous positive airway pressure), sputum induction, and other procedures that might result in the generation of aerosols.
**	Reasons for testing are not mutually exclusive. Other reasons for testing included screening before or after travel, testing because of
symptoms after receipt of a Covid-19 vaccine, or not specified.
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Table 3. Estimated Effectiveness of mRNA Vaccines among Health Care Personnel, According to Covid-19 Vaccination
Status among Case and Control Participants.*
Case
Participants
(N = 1472)

Variable

Control
Participants
(N = 3420)

Vaccine Effectiveness (95% CI)
Unadjusted Analysis

number (percent)

Adjusted Analysis†

percent

Receipt of any Covid-19 vaccine
One dose <10 days before test date

249 (17)

375 (11)

25.0 (7.3 to 39.3)

12.8 (−9.4 to 30.5)

One dose 10–13 days before test date

104 (7)

220 (6)

44.1 (26.2 to 57.7)

36.8 (14.8 to 53.1)

Partial vaccination

140 (10)

863 (25)

81.3 (76.5 to 85.1)

79.7 (74.1 to 84.1)

Complete vaccination

167 (11)

1072 (31)

90.2 (87.0 to 92.6)

90.4 (87.0 to 92.9)

BNT162b2 vaccine
Partial vaccination

122 (8)

707 (21)

79.4 (73.7 to 83.9)

77.6 (70.9 to 82.7)

Complete vaccination

149 (10)

882 (26)

88.9 (85.1 to 91.7)

88.8 (84.6 to 91.8)

mRNA-1273 vaccine
Partial vaccination

18 (1)

156 (5)

89.8 (81.1 to 94.4)

88.9 (78.7 to 94.2)

Complete vaccination

18 (1)

190 (6)

95.7 (90.4 to 98.0)

96.3 (91.3 to 98.4)

*	Effectiveness of the messenger RNA (mRNA) vaccines was calculated as 1 minus the matched odds ratio (× 100%)
for partial or complete vaccination, as compared with no vaccination, and was estimated with the use of a conditional
logistic-regression model with accounting for matching according to site of enrollment and week of test date. Vaccine
effectiveness for all categories was estimated with the use of unvaccinated participants as a reference group. For partial
vaccination, the effectiveness of a single dose was assessed during the interval from 14 days after receipt of the first
dose through 6 days after receipt of the second dose. For complete vaccination, the effectiveness of two doses was as‑
sessed at least 7 days after receipt of the second dose (consistent with the Pfizer–BioNTech clinical trial7). CI denotes
confidence interval.
†	The odds ratio was adjusted for age, race and ethnic group, presence of underlying conditions, and close contact with
patients with Covid-19 in the workplace or persons with Covid-19 outside the workplace.

90.9% (95% CI, 87.2 to 93.5), results that were
similar to those of the primary analysis. The
exclusion of case and control participants who
reported positive serologic (antibody) test results
during the interview did not change the vaccine
effectiveness for partial vaccination (79.7%; 95%
CI, 74.1 to 84.1) or complete vaccination (90.5%;
95% CI, 87.1 to 93.0).
We evaluated vaccine effectiveness according
to subgroup and according to clinical case definition (Tables 4 and S4). The adjusted effectiveness for partial vaccination or complete vaccination was similar in subgroups defined according
to age (<50 years and ≥50 years), race and ethnic
group, presence of underlying conditions, and
level of patient contact. Owing to the limited
number of pregnant participants, vaccine effectiveness was estimated in a subgroup that included both partially and completely vaccinated
participants (77.1%; 95% CI, 32.2 to 92.2). In a
combined group of partially and completely vaccinated participants with immunocompromisn engl j med 385;25

ing conditions, vaccine effectiveness was 39.1%
(95% CI, −45.0 to 74.4).
To evaluate evidence of waning of vaccine effect, we estimated effectiveness every 2 weeks
during the 14 total weeks of follow-up available
immediately after receipt of the second dose
(Fig. 1). The point estimate of vaccine effectiveness, assessed in 2-week intervals, was highest
during weeks 3 and 4 after receipt of the second
dose (96.3%; 95% CI, 92.5 to 98.2). The point
estimates were lower during weeks 9 through
14, but the 95% confidence intervals were wide
and overlapping.

Discussion
In this multisite, test-negative case–control study,
we found that both the BNT162b2 and mRNA1273 vaccines were highly effective against symptomatic Covid-19 among health care personnel.
The effectiveness estimates were similar across racial and ethnic groups, among persons with under-
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an increased risk of severe Covid-19, and in subgroups defined according to various levels of patient contact, including substantial direct contact
with patients. Our results showed that the effectiveness of a two-dose regimen with the BNT162b2
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vaccine was 89% and that with the mRNA-1273
vaccine was 96%, findings that are consistent with
efficacy results from phase 3 trials.7,8
Evidence from postintroduction effectiveness
studies has been accruing rapidly. These studies
have shown that in a real-world setting, both of

Table 4. Estimated Effectiveness of mRNA Vaccines among Health Care Personnel in Subgroups Defined According to Risk Factors, Age
Group, and Race and Ethnic Group.*
Case
Participants
(N = 1472)

Variable

Control
Participants
(N = 3420)

Vaccine Effectiveness (95% CI)
Unadjusted Analysis

no./total no. (%)

Adjusted Analysis†

percent

Risk factors
Underlying condition or risk factor that increases risk
of severe Covid-19‡
≥1 Underlying condition or risk factor
Partial vaccination

110/1126 (10)

627/2561 (24)

79.3 (73.2 to 84.0)

76.4 (69.0 to 82.0)

Complete vaccination

118/1126 (10)

784/2561 (31)

90.1 (85.8 to 92.7)

90.3 (86.4 to 93.0)

≥2 Underlying conditions or risk factors
Partial vaccination

69/697 (10)

409/1639 (25)

81.1 (72.7 to 85.5)

76.7 (67.4 to 83.3)

Complete vaccination

80/697 (11)

500/1639 (31)

88.8 (84.0 to 92.2)

88.5 (83.2 to 92.2)

Partial vaccination

43/407 (11)

235/944 (25)

79.6 (69.5 to 86.4)

76.1 (63.4 to 84.3)

Complete vaccination

50/407 (12)

298/944 (32)

89.5 (83.7 to 93.3)

89.4 (83.1 to 93.4)

30/346 (9)

236/859 (27)

87.0 (79.4 to 91.8)

87.5 (79.7 to 92.3)

≥3 Underlying conditions or risk factors

No underlying condition or risk factor
Partial vaccination
Complete vaccination

49/346 (14)

288/859 (34)

91.0 (85.8 to 94.3)

91.1 (85.5 to 94.6)

23/64 (36)

58/124 (47)

52.4 (−6.4 to 78.7)

39.1 (−45.0 to 74.4)

Partial vaccination

47/529 (9)

254/1068 (24)

81.6 (72.9 to 87.5)

80.2 (70.3 to 86.8)

Complete vaccination

49/529 (9)

321/1068 (30)

91.2 (86.6 to 94.2)

92.1 (87.6 to 95.0)

Any immunocompromising condition, assessed for
partial and complete vaccination§¶
Obesity‖

Obesity or overweight‖
Partial vaccination

97/954 (10)

490/2022 (24)

78.2 (71.2 to 83.5)

76.5 (68.4 to 82.5)

Complete vaccination

93/954 (10)

633/2022 (31)

90.7 (87.0 to 93.4)

91.0 (87.0 to 93.7)

Partial vaccination

17/215 (8)

120/485 (25)

85.8 (74.1 to 92.2)

83.1 (68.1 to 91.0)

Complete vaccination

22/215 (10)

148/485 (31)

91.3 (83.7 to 95.3)

91.8 (83.9 to 95.8)

Hypertension

Asthma
Partial vaccination

20/207 (10)

155/616 (25)

81.8 (67.6 to 89.7)

77.8 (59.5 to 87.8)

Complete vaccination

21/207 (10)

175/616 (28)

90.7 (82.8 to 94.9)

90.5 (81.9 to 95.0)

4/69 (6)

42/159 (26)

89.0 (64.9 to 96.5)

85.5 (52.3 to 95.6)

Diabetes
Partial vaccination
Complete vaccination
Pregnancy, assessed for partial and complete vaccination¶

e90(8)

10/69 (14)

42/159 (26)

79.2 (48.2 to 91.7)

80.2 (45.8 to 92.7)

6/62 (10)

28/91 (31)

83.8 (54.5 to 94.2)

77.1 (32.2 to 92.2)
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Table 4. (Continued.)
Case
Participants
(N = 1472)

Variable

Control
Participants
(N = 3420)

Vaccine Effectiveness (95% CI)
Unadjusted Analysis

no./total no. (%)

Adjusted Analysis†

percent

Age
<50 yr
Partial vaccination

106/1128 (9)

644/2568 (25)

81.5 (76.1 to 85.7)

80.3 (74.2 to 85.0)

Complete vaccination

130/1128 (12)

810/2568 (32)

90.2 (86.6 to 92.7)

90.3 (86.5 to 93.0)

Partial vaccination

34/331 (10)

205/816 (25)

78.6 (66.1 to 86.5)

77.0 (62.7 to 85.8)

Complete vaccination

36/331 (11)

256/816 (31)

89.0 (82.0 to 93.3)

90.7 (84.2 to 94.6)

Partial vaccination

103/973 (11)

641/2478 (26)

79.7 (73.4 to 84.5)

79.3 (72.5 to 84.4)

Complete vaccination

127/973 (13)

815/2478 (33)

89.5 (85.5 to 92.3)

90.1 (86.2 to 93.0)

≥50 yr

Race and ethnic group
White, non-Hispanic

Black, non-Hispanic
Partial vaccination

7/188 (4)

40/259 (15)

85.3 (64.9 to 93.9)

85.7 (64.7 to 94.2)

Complete vaccination

6/188 (3)

44/259 (17)

94.4 (82.7 to 98.2)

94.8 (83.3 to 98.4)

Hispanic or Latino
Partial vaccination

12/157 (8)

69/281 (25)

81.3 (61.1 to 91.0)

81.6 (60.5 to 91.5)

Complete vaccination

16/157 (10)

74/281 (26)

86.4 (73.1 to 93.1)

89.4 (78.0 to 94.9)

9/84 (11)

74/268 (28)

80.5 (54.3 to 91.7)

79.6 (50.4 to 91.6)

11/84 (13)

99/268 (37)

90.3 (77.4 to 95.9)

89.3 (74.2 to 95.6)

Partial vaccination

5/34 (15)

13/47 (28)

78.3 (5.8 to 95.0)

75.9 (−7.7 to 94.6)

Complete vaccination

6/34 (18)

1/47 (2)

91.0 (57.3 to 98.1)

93.7 (69.4 to 98.7)

Asian or Pacific Islander, non-Hispanic
Partial vaccination
Complete vaccination
American Indian or Alaska Native, non-Hispanic

*	Vaccine effectiveness was calculated as 1 minus the matched odds ratio (× 100%) for partial or complete vaccination, as compared with no
vaccination, and was estimated with the use of a conditional logistic-regression model with accounting for matching according to site of
enrollment and week of test date. The reference group in the analysis of effectiveness in all categories was the group of unvaccinated partici‑
pants. For partial vaccination, the effectiveness of a single dose was assessed during the interval from 14 days after receipt of the first dose
through 6 days after receipt of the second dose. For complete vaccination, the effectiveness of two doses was assessed at least 7 days after
the receipt of the second dose (consistent with the Pfizer–BioNTech clinical trial7).
†	The odds ratio was adjusted for age, race and ethnic group, presence of underlying conditions, and close contact with patients with
Covid-19 in the workplace or persons with Covid-19 outside the workplace.
‡	We defined conditions as being associated with a definite or potential increased risk of severe Covid-19 according to the definitions of the Centers
for Disease Control and Prevention (https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html).
§	Immunocompromising conditions included receipt of immunosuppressive medication (e.g., glucocorticoids, chemotherapy, or other immu‑
nosuppressive medication), solid-organ transplantation, hematopoietic stem-cell transplantation, human immunodeficiency virus infection,
or active cancer (current cancer or treatment for cancer or receipt of diagnosis in the preceding 12 months).
¶	The sample size was limited for the evaluation of effectiveness according to vaccination status. Therefore, vaccine effectiveness was as‑
sessed in the interval from at least 14 days after receipt of the first dose through the receipt of the second dose or later.
‖	Obesity was defined as a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher, and
overweight as a BMI of 25 to 29.

these mRNA vaccines work well, and the effec- tions16,17 and using different study designs9,18,19
tiveness of these vaccines among persons who and case definitions.20,21
are completely vaccinated is consistent across
Although Covid-19 vaccines have been recomobservational studies involving different popula- mended for adults with chronic medical condin engl j med 385;25
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Figure 1. Estimated Adjusted Effectiveness of mRNA Vaccines against
Covid-19 among Health Care Personnel According to Follow-up Time
after Receipt of the Second Dose.
Vaccine effectiveness was calculated as 1 minus the matched odds ratio for
partial or complete vaccination, as compared with no vaccination, and was
estimated with the use of a conditional logistic-regression model with ac‑
counting for matching according to site of enrollment and week of test date.
The effectiveness of messenger RNA (mRNA) vaccines in all categories
was estimated in 2-week intervals of follow-up with the use of unvaccinated
participants as a reference group. The odds ratio was adjusted for age, race
and ethnic group, presence of underlying conditions, and close contact
with patients with coronavirus disease 2019 (Covid-19) in the workplace
or persons with Covid-19 outside the workplace. I bars indicate 95% con
fidence intervals.

tions,22 little has been known about the effectiveness of vaccines among adults with individual
risk factors for severe outcomes of Covid-19.15
Phase 3 trials showed vaccine efficacy in a group
of adults with at least one at-risk condition,7,8
and few observational studies9,23 to date have been
powered to evaluate effectiveness among persons
with specific underlying conditions. Our study
results showed that complete vaccination with
mRNA vaccines was effective in adults with
more than one risk factor for severe Covid-19; in
adults with obesity, hypertension, asthma, or
diabetes; and in adults 50 years of age or older.
Among health care personnel with immunocompromising conditions, the estimated vaccine effectiveness was low and had confidence intervals
that included the null value; these results are
consistent with recent studies showing a poor
immune response to mRNA vaccines in immunocompromised persons.24,25
Our study showed that mRNA vaccines were
effective in pregnant women who were come90(10)
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pletely or partially vaccinated; the effectiveness
among completely vaccinated pregnant women
is probably higher than the estimate in our study.
Older persons, those with chronic medical conditions, and pregnant women have been recognized during this pandemic as groups at increased
risk for severe outcomes of Covid-19,26 and the
availability of highly effective vaccines has the
potential of reducing mortality and the incidence
of hospitalization associated with Covid-19 in
these populations.
The effectiveness of partial vaccination, estimated in this study at 78% with the BNT162b2
vaccine and at 89% with the mRNA-1273 vaccine, was higher than the estimates from the
respective phase 3 trials.7,8 Although 90% and
94% of the case participants who were included
in this study would meet the case definitions of
the Pfizer–BioNTech and Moderna phase 3 trials,
respectively, our study population was younger
(76% of the participants were <50 years of age)
and the proportion of participants with chronic
underlying conditions was lower than those in
the trial populations.7,8 In addition, when the
efficacy data for a single dose of the BNT162b2
vaccine were reanalyzed with restriction to cases
that occurred at least 14 days after receipt of the
first dose (instead of at ≥0 days after receipt of
the first dose, as in the initial trial analysis), the
efficacy was measured at 92.6%.27 Several cohort
studies involving health care personnel have shown
effectiveness estimates of partial vaccination
with two mRNA vaccines that are consistent with
our findings.19,28-33 The high effectiveness of partial vaccination in our study should be interpreted with caution owing to the short window
of risk after the receipt of a single dose, given
that overall adherence to the recommended administration interval was high (i.e., 21 days for
the BNT162b2 vaccine and 28 days for the
mRNA-1273 vaccine).34
The effectiveness estimates in our study and
in other studies were based on a relatively short
follow-up; it is unknown how long this level of
protection from either vaccine will last, especially
among persons with immunocompromising conditions or among older persons. In this relatively young population of health care personnel,
we did not find strong evidence of decreasing
effectiveness during the 14 weeks of observation
after receipt of the second dose. Although effectiveness estimates during weeks 9 through 14
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were lower than the maximum vaccine effectiveness that was observed during weeks 3 and 4,
wide and overlapping confidence intervals do not
support a conclusion of waning immunity but do
warrant longer-term monitoring of vaccine effects.
The findings of this study are subject to
limitations. First, the testing of health care personnel for SARS-CoV-2 was based on occupational health practices at each facility. Although
participating sites did not report any changes in
routine testing practices after the introduction
of vaccines, if vaccinated health care personnel
were less likely to seek testing than those who
were unvaccinated, the vaccine effectiveness
could be underestimated. Alternatively, if postvaccination systemic reactions led to vaccinated
health care personnel being more likely to seek
testing, vaccine effectiveness could be overestimated. A sensitivity analysis that excluded the
time window when most postvaccination reactions are expected to occur (0 to 2 days after
receipt of the second dose) resulted in estimates
of vaccine effectiveness similar to those in the
primary analysis. Second, although the study
excluded health care personnel with a known
history of acute SARS-CoV-2 infection, persons
with unknown previous infection could not be
excluded. A sensitivity analysis that excluded
participants who reported having a positive result for SARS-CoV-2 on serologic testing resulted
in estimates of vaccine effectiveness similar to
those in the primary analysis, although the number of participants reporting positive serologic
tests was small.
Strengths of the study include its large sample
size, which allowed for adjustment of confounding and for estimation of vaccine effectiveness in
various subgroups of health care personnel, and
broad geographic coverage representing the U.S.
population. Although we controlled for potential
confounders by carefully selecting factors that
are common causes of exposure and SARS-CoV-2
infection and, in the final model, selecting from
those on the basis of a “change in estimate” ap-

proach, there are limitations to this method.35
We had small sample sizes in subgroups of participants with selected underlying conditions, and
it will be useful to investigate the reproducibility
of these results in future studies. Studies focusing
on persons with immunocompromising conditions are needed to understand how well Covid-19
vaccines work in these groups of persons at high
risk for severe outcomes of Covid-19. Studies
with longer follow-up are necessary for understanding the long-term duration of vaccine effect.
Our study showed that vaccination with either
the BNT162b2 or mRNA-1273 vaccine was highly effective in preventing symptomatic Covid-19,
a finding that is consistent with the results of
phase 3 trials.7,8 Our study also provided additional support to the evidence accruing from
observational studies. In this population of health
care personnel, vaccine effectiveness was similar
among persons with underlying medical conditions or other risk factors for severe Covid-19,
including pregnancy; in different subgroups of
health care personnel defined according to job
category; and in racial and ethnic groups that
have been disproportionately affected by the pandemic. The long-term duration of protection and
the effectiveness of these vaccines against emerging variants is unknown and should be monitored
to indicate whether changes to vaccine composition or vaccine policy are needed.
The findings and conclusions in this article are those of the
authors and do not necessarily represent the official position
of the Centers for Disease Control and Prevention (CDC). The
activity reported in this article was deemed not to be research
as defined in 45 Code of Federal Regulations (CFR) 46.102(l),
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example, 45 CFR part 46, 21 CFR part 56, 42 U.S. Code section 241(d), 5 U.S. Code section 552a, and 44 U.S. Code §3501
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